Clinical relevance of the putative stem cell marker p63 in breast cancer

Breast Cancer Research and Treatment

Volumn 122, Issue 3, 2010, Pages 765-775

  Hanker, L ^a   Karn, T ^a   Ruckhaeberle, E ^a   Gaetje, R ^a   Solbach, C ^a   Schmidt, M ^b   Engels, K ^a   Holtrich, U ^a   Kaufmann, M ^a   Rody, A ^a  

^a GOETHE UNIVERSITY   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Benign tissue; Microarray; p63; Stem cell; TP73L

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROTEIN P63; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE MARKER; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MICROARRAY; TREATMENT RESPONSE; BREAST TUMOR; COHORT ANALYSIS; ENZYME IMMUNOASSAY; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE;

BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASTIC STEM CELLS; PROGNOSIS; RECEPTORS, ESTROGEN; SURVIVAL RATE; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; TRANSCRIPTION FACTORS;

EID: 77955551438     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0608-6     Document Type: Article

References (76)

1. F McKeon G Melino 2007 Fog of war: the emerging p53 family Cell cycle 6 3 229 232 1:CAS:528:DC%2BD2sXnvFygtrc%3D 17297295
2. LE Finlan TR Hupp 2007 p63: the phantom of the tumor suppressor Cell cycle 6 9 1062 1071 1:CAS:528:DC%2BD2sXhtVSgu7rK 17426453
3. KE King WC Weinberg 2007 p63: defining roles in morphogenesis, homeostasis, and neoplasia of the epidermis Mol Carcinog 46 8 716 724 10.1002/mc.20337 1:CAS:528:DC%2BD2sXpvFyktrw%3D 17477357 (Pubitemid 47255193)
4. A Yang M Kaghad Y Wang E Gillett MD Fleming V Dotsch NC Andrews D Caput F McKeon 1998 p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities Mol cell 2 3 305 316 10.1016/S1097-2765(00)80275-0 1:CAS:528:DyaK1cXmsVyqt7c%3D 9774969
5. JC Bourdon 2007 p53 and its isoforms in cancer Br J Cancer 97 3 277 282 10.1038/sj.bjc.6603886 1:CAS:528:DC%2BD2sXotlSgt78%3D 17637683 (Pubitemid 47196755)
6. ER Flores KY Tsai D Crowley S Sengupta A Yang F McKeon T Jacks 2002 p63 and p73 are required for p53-dependent apoptosis in response to DNA damage Nature 416 6880 560 564 10.1038/416560a 1:CAS:528:DC%2BD38XivVOnu7o%3D 11932750 (Pubitemid 34288861)
7. MS Irwin WG Kaelin Jr 2001 Role of the newer p53 family proteins in malignancy Apoptosis 6 1-2 17 29 10.1023/A:1009663809458 1:CAS:528: DC%2BD3MXivVGrsL4%3D 11321038 (Pubitemid 32233952)
8. A Yang R Schweitzer D Sun M Kaghad N Walker RT Bronson C Tabin A Sharpe D Caput C Crum, et al. 1999 p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development Nature 398 6729 714 718 10.1038/19539 1:CAS:528:DyaK1MXivVegtbY%3D 10227294 (Pubitemid 29197650)
9. F McKeon 2004 p63 and the epithelial stem cell: more than status quo? Genes Dev 18 5 465 469 10.1101/gad.1190504 1:CAS:528:DC%2BD2cXis1Kns7s%3D 15037544 (Pubitemid 38372803)
10. M Barbareschi L Pecciarini MG Cangi E Macri A Rizzo G Viale C Doglioni 2001 p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast Am J Surg Pathol 25 8 1054 1060 10.1097/00000478-200108000- 00010 1:STN:280:DC%2BD3MvislShug%3D%3D 11474290 (Pubitemid 32685903)
11. J DiRenzo S Signoretti N Nakamura R Rivera-Gonzalez W Sellers M Loda M Brown 2002 Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line Cancer Res 62 1 89 98 1:CAS:528: DC%2BD38XntV2jug%3D%3D 11782364
12. AA Mills B Zheng XJ Wang H Vogel DR Roop A Bradley 1999 p63 is a p53 homologue required for limb and epidermal morphogenesis Nature 398 6729 708 713 10.1038/19531 1:CAS:528:DyaK1MXivVegtbo%3D 10227293 (Pubitemid 29197649)
13. I Matos R Dufloth M Alvarenga LC Zeferino F Schmitt 2005 p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas Virchows Arch 447 4 688 694 10.1007/s00428-005-0010-7 1:CAS:528:DC%2BD2MXhtFKqt7zM 16012853 (Pubitemid 41571183)
14. T Sorlie CM Perou R Tibshirani T Aas S Geisler H Johnsen T Hastie MB Eisen M van de Rijn SS Jeffrey, et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 10869 10874 10.1073/pnas.191367098 1:CAS:528: DC%2BD3MXntVGmsbo%3D 11553815 (Pubitemid 32878711)
15. A Ribeiro-Silva LN Zambelli Ramalho S Britto Garcia S Zucoloto 2003 The relationship between p63 and p53 expression in normal and neoplastic breast tissue Arch Pathol Lab Med 127 3 336 340 1:CAS:528:DC%2BD3sXjtVyqsr0%3D 12653579
16. JS Reis-Filho F Milanezi J Paredes P Silva EM Pereira SA Maeda LV De Carvalho FC Schmitt 2003 Novel and classic myoepithelial/stem cell markers in metaplastic carcinomas of the breast Appl Immunohistochem Mol Morphol 11 1 1 8 10.1097/00022744-200303000-00001 1:CAS:528:DC%2BD3sXhs1ansrg%3D 12610349 (Pubitemid 36372997)
17. ER Flores S Sengupta JB Miller JJ Newman R Bronson D Crowley A Yang F McKeon T Jacks 2005 Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family Cancer Cell 7 4 363 373 10.1016/j.ccr.2005.02.019 1:CAS:528:DC%2BD2MXjvFSku7w%3D 15837625 (Pubitemid 40544653)
18. WM Keyes H Vogel MI Koster X Guo Y Qi KM Petherbridge DR Roop A Bradley AA Mills 2006 p63 heterozygous mutant mice are not prone to spontaneous or chemically induced tumors Proc Natl Acad Sci USA 103 22 8435 8440 10.1073/pnas.0602477103 1:CAS:528:DC%2BD28XlvFChtL4%3D 16714381 (Pubitemid 43838473)
19. K Yamaguchi L Wu OL Caballero K Hibi B Trink V Resto P Cairns K Okami WM Koch D Sidransky, et al. 2000 Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma Int J Cancer 86 5 684 689 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M 1:CAS:528:DC%2BD3cXjslSlsLg%3D 10797291 (Pubitemid 30249880)
20. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Nozoe T, Yasumoto K (2006) Expression of the p53 family in lung cancer. Anticancer Res 26(3A):1785-1790
21. Y Takeuchi A Tamura M Kamiya T Fukuda O Ishikawa 2005 Immunohistochemical analyses of p63 expression in cutaneous tumours Br J Dermatol 153 6 1230 1232 10.1111/j.1365-2133.2005.06952.x 1:STN:280:DC%2BD2MnislSmtw%3D%3D 16307669 (Pubitemid 41779588)
22. Z Lin M Liu Z Li C Kim E Lee I Kim 2006 DeltaNp63 protein expression in uterine cervical and endometrial cancers J Cancer Res Clin Oncol 132 12 811 816 10.1007/s00432-006-0130-8 1:CAS:528:DC%2BD28XhtVeqsb7P 16804722 (Pubitemid 44521457)
23. BJ Quade A Yang Y Wang D Sun J Park EE Sheets A Cviko JM Federschneider R Peters FD McKeon, et al. 2001 Expression of the p53 homologue p63 in early cervical neoplasia Gynecol Oncol 80 1 24 29 10.1006/gyno.2000.5953 1:CAS:528:DC%2BD3MXntl2q 11136565 (Pubitemid 32062084)
24. JS Reis-Filho FC Schmitt 2003 p63 expression in sarcomatoid/metaplastic carcinomas of the breast Histopathology 42 1 94 95 10.1046/j.1365-2559.2003. 01513-2.x 1:STN:280:DC%2BD38jjtVKhtg%3D%3D 12493033 (Pubitemid 36062575)
25. Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kakudo K (2002) p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 9(3):216-219
26. AA Mills 2006 p63 oncogene or tumor suppressor? Curr Opin Genet Dev 16 1 38 44 10.1016/j.gde.2005.12.001 1:CAS:528:DC%2BD28XlvVOhsw%3D%3D 16359856 (Pubitemid 43089610)
27. Karn T, Metzler D, Ruckhaberle E, Hanker L, Gatje R, Solbach C, Ahr A, Schmidt M, Holtrich U, Kaufmann M et al (2009) Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0416-z
28. A Ahr T Karn C Solbach T Seiter K Strebhardt U Holtrich M Kaufmann 2002 Identification of high risk breast-cancer patients by gene expression profiling Lancet 359 9301 131 132 10.1016/S0140-6736(02)07337-3 11809257 (Pubitemid 34112543)
29. Rody A, Holtrich U, Gaetje R, Gehrmann M, Engels K, von Minckwitz G, Loibl S, Diallo-Danebrock R, Ruckhaberle E, Metzler D et al (2007) Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1 (2007) Clin Cancer Res 13(4):1115-1122
30. Rody A, Karn T, Ruckhaberle E, Hanker L, Metzler D, Muller V, Solbach C, Ahr A, Gatje R, Holtrich U et al (2009) Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers-results of a large scale microarray analysis. Eur J Cancer 45(3):405-413
31. A Rody T Karn C Solbach R Gaetje M Munnes S Kissler E Ruckhaberle GV Minckwitz S Loibl U Holtrich, et al. 2007 The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial Breast 16 3 235 240 10.1016/j.breast.2007.02.006 1:STN:280:DC%2BD2szis12gsw%3D%3D 17449250 (Pubitemid 46796861)
32. E Ruckhaberle A Rody K Engels R Gaetje G von Minckwitz S Schiffmann S Grosch G Geisslinger U Holtrich T Karn, et al. 2008 Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer Breast Cancer Res Treat 112 1 41 52 10.1007/s10549-007-9836-9 18058224
33. Y Wang JG Klijn Y Zhang AM Sieuwerts MP Look F Yang D Talantov M Timmermans ME Meijer-van Gelder J Yu, et al. 2005 Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer Lancet 365 9460 671 679 1:CAS:528:DC%2BD2MXhsVOitLk%3D 15721472
34. AJ Minn GP Gupta D Padua P Bos DX Nguyen D Nuyten B Kreike Y Zhang Y Wang H Ishwaran, et al. 2007 Lung metastasis genes couple breast tumor size and metastatic spread Proc Natl Acad Sci U S A 104 16 6740 6745 10.1073/pnas. 0701138104 1:CAS:528:DC%2BD2sXkvFWjsbo%3D 17420468 (Pubitemid 47175571)
35. CJ Creighton C Kent Osborne MJ van de Vijver JA Foekens JG Klijn HM Horlings D Nuyten Y Wang Y Zhang GC Chamness, et al. 2009 Molecular profiles of progesterone receptor loss in human breast tumors Breast Cancer Res Treat 114 2 287 299 10.1007/s10549-008-0017-2 1:CAS:528:DC%2BD1MXhsFWnu7g%3D 18425577
36. M Schmidt D Bohm C von Torne E Steiner A Puhl H Pilch HA Lehr JG Hengstler H Kolbl M Gehrmann 2008 The humoral immune system has a key prognostic impact in node-negative breast cancer Cancer Res 68 13 5405 5413 10.1158/0008-5472.CAN-07-5206 1:CAS:528:DC%2BD1cXnvFyjtb4%3D 18593943
37. C Desmedt F Piette S Loi Y Wang F Lallemand B Haibe-Kains G Viale M Delorenzi Y Zhang MS d'Assignies, et al. 2007 Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series Clin Cancer Res 13 11 3207 3214 10.1158/1078-0432.CCR-06-2765 1:CAS:528:DC%2BD2sXmtVajur0%3D 17545524 (Pubitemid 46944903)
38. C Sotiriou P Wirapati S Loi A Harris S Fox J Smeds H Nordgren P Farmer V Praz B Haibe-Kains, et al. 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis J Natl Cancer Inst 98 4 262 272 10.1093/jnci/djj052 1:CAS:528:DC%2BD28Xhs1Skt74%3D 16478745 (Pubitemid 43264710)
39. S Loi B Haibe-Kains C Desmedt P Wirapati F Lallemand AM Tutt C Gillet P Ellis K Ryder JF Reid, et al. 2008 Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen BMC Genomics 9 239 10.1186/1471-2164-9-239 18498629 (Pubitemid 351804039)
40. S Loi B Haibe-Kains C Desmedt F Lallemand AM Tutt C Gillet P Ellis A Harris J Bergh JA Foekens, et al. 2007 Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade J Clin Oncol 25 10 1239 1246 10.1200/JCO.2006.07.1522 1:CAS:528:DC%2BD2sXkvFyms7w%3D 17401012 (Pubitemid 46640570)
41. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J et al (2009) The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116:303-309
42. Y Pawitan J Bjohle L Amler AL Borg S Egyhazi P Hall X Han L Holmberg F Huang S Klaar, et al. 2005 Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts Breast Cancer Res 7 6 R953 R964 10.1186/bcr1325 1:CAS:528: DC%2BD2MXht1WmsrjM 16280042
43. LD Miller J Smeds J George VB Vega L Vergara A Ploner Y Pawitan P Hall S Klaar ET Liu, et al. 2005 An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival Proc Natl Acad Sci USA 102 38 13550 13555 10.1073/pnas.0506230102 1:CAS:528:DC%2BD2MXhtVygtr7I 16141321 (Pubitemid 41420886)
44. AV Ivshina J George O Senko B Mow TC Putti J Smeds T Lindahl Y Pawitan P Hall H Nordgren, et al. 2006 Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer Cancer Res 66 21 10292 10301 10.1158/0008-5472.CAN-05-4414 1:CAS:528:DC%2BD28XhtFGjsrjM 17079448 (Pubitemid 44799747)
45. K Chin S DeVries J Fridlyand PT Spellman R Roydasgupta WL Kuo A Lapuk RM Neve Z Qian T Ryder, et al. 2006 Genomic and transcriptional aberrations linked to breast cancer pathophysiologies Cancer Cell 10 6 529 541 10.1016/j.ccr.2006. 10.009 1:CAS:528:DC%2BD28XhtlCnsrbF 17157792 (Pubitemid 44854748)
46. AJ Minn GP Gupta PM Siegel PD Bos W Shu DD Giri A Viale AB Olshen WL Gerald J Massague 2005 Genes that mediate breast cancer metastasis to lung Nature 436 7050 518 524 10.1038/nature03799 1:CAS:528:DC%2BD2MXmsFCgs7o%3D 16049480 (Pubitemid 41112921)
47. KR Hess K Anderson WF Symmans V Valero N Ibrahim JA Mejia D Booser RL Theriault AU Buzdar PJ Dempsey, et al. 2006 Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer J Clin Oncol 24 26 4236 4244 10.1200/JCO.2006.05.6861 1:CAS:528:DC%2BD28XhtVGju7vJ 16896004 (Pubitemid 46630780)
48. P Farmer H Bonnefoi V Becette M Tubiana-Hulin P Fumoleau D Larsimont G Macgrogan J Bergh D Cameron D Goldstein, et al. 2005 Identification of molecular apocrine breast tumours by microarray analysis Oncogene 24 29 4660 4671 10.1038/sj.onc.1208561 1:CAS:528:DC%2BD2MXlvVGhsLc%3D 15897907 (Pubitemid 41032603)
49. WR Miller AA Larionov L Renshaw TJ Anderson S White J Murray E Murray G Hampton JR Walker S Ho, et al. 2007 Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole Pharmacogenet Genomics 17 10 813 826 10.1097/FPC.0b013e32820b853a 1:CAS:528:DC%2BD2sXhtVKhsLfM 17885619 (Pubitemid 47462295)
50. The International Genomics Consortium (IGC) (2005) The expO project (expression project for oncology) http://www.intgen.org/
51. K Yu K Ganesan LK Tan M Laban J Wu XD Zhao H Li CH Leung Y Zhu CL Wei, et al. 2008 A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers PLoS Genet 4 7 e1000129 10.1371/journal.pgen.1000129 18636107
52. Gene Expression Omnibus Series GSE12763 (2009) http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE12763
53. AL Richardson ZC Wang A De Nicolo X Lu M Brown A Miron X Liao JD Iglehart DM Livingston S Ganesan 2006 X chromosomal abnormalities in basal-like human breast cancer Cancer Cell 9 2 121 132 10.1016/j.ccr.2006.01.013 1:CAS:528:DC%2BD28XhvFynsrg%3D 16473279 (Pubitemid 43202662)
54. A Klein R Wessel M Graessmann M Jurgens I Petersen R Schmutzler D Niederacher N Arnold A Meindl S Scherneck, et al. 2007 Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set Int J Cancer 121 3 683 688 10.1002/ijc.22630 1:CAS:528:DC%2BD2sXnt1CrsrY%3D 17410534 (Pubitemid 46986504)
55. B Marty V Maire E Gravier G Rigaill A Vincent-Salomon M Kappler I Lebigot F Djelti A Tourdes P Gestraud, et al. 2008 Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells Breast Cancer Res 10 6 R101 10.1186/bcr2204 19055754
56. Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, Rubio R, Wang T, Agrawal D, McCarthy SM, Gruidl M et al (2009) Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat. doi: 10.1007/s10549-009-0344-y
57. Affymetrix (2001) Statistical algorithms reference guide, Technical report. Affymetrix, Santa Clara
58. L Gautier L Cope BM Bolstad RA Irizarry 2004 affy-analysis of Affymetrix GeneChip data at the probe level Bioinformatics 20 3 307 315 10.1093/bioinformatics/btg405 1:CAS:528:DC%2BD2cXht1Kksr4%3D 14960456 (Pubitemid 38262761)
59. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J et al (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5(10):R80
60. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA (2006) Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 66(15):7589-7597
61. Yang A, Zhu Z, Kapranov P, McKeon F, Church GM, Gingeras TR, Struhl K (2006) Relationships between p63 binding, DNA sequence, transcription activity, and biological function in human cells. Mol Cell 24(4):593-602
62. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 2 229 235 10.1007/s10549-006-9242-8 16932852 (Pubitemid 44631925)
63. E Debus K Weber M Osborn 1982 Monoclonal cytokeratin antibodies that distinguish simple from stratified squamous epithelia: characterization on human tissues The EMBO journal 1 12 1641 1647 1:CAS:528:DyaL3sXoslektg%3D%3D 6202511
64. RB Nagle W Bocker JR Davis HW Heid M Kaufmann DO Lucas ED Jarasch 1986 Characterization of breast carcinomas by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells J Histochem Cytochem 34 7 869 881 1:CAS:528:DyaL28XksVSksb8%3D 2423579
65. DM Abd El-Rehim SE Pinder CE Paish J Bell RW Blamey JF Robertson RI Nicholson IO Ellis 2004 Expression of luminal and basal cytokeratins in human breast carcinoma J Pathol 203 2 661 671 10.1002/path.1559 15141381 (Pubitemid 38714103)
66. A Ribeiro-Silva LN Ramalho SB Garcia DF Brandao F Chahud S Zucoloto 2005 p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer Histopathology 47 5 458 466 10.1111/j.1365-2559.2005.02249.x 1:STN:280:DC%2BD2MrmsFKksg%3D%3D 16241993 (Pubitemid 41626723)
67. JS Reis-Filho PT Simpson A Martins A Preto F Gartner FC Schmitt 2003 Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray Virchows Arch 443 2 122 132 10.1007/s00428-003-0859-2 1:CAS:528: DC%2BD3sXmsVSiurg%3D 12884041 (Pubitemid 37056135)
68. KA Czkowski KL Ferguson DD Grier D Hossain SS Banerjee JE McNeal DG Bostwick 2003 Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases Am J Surg Pathol 27 12 1523 1529 10.1097/00000478-200312000-00004 (Pubitemid 37486613)
69. K Hibi B Trink M Patturajan WH Westra OL Caballero DE Hill EA Ratovitski J Jen D Sidransky 2000 AIS is an oncogene amplified in squamous cell carcinoma Proc Natl Acad Sci USA 97 10 5462 5467 10.1073/pnas.97.10.5462 1:CAS:528:DC%2BD3cXjsVWmsrs%3D 10805802 (Pubitemid 30313741)
70. M Senoo I Tsuchiya Y Matsumura T Mori Y Saito H Kato T Okamoto S Habu 2001 Transcriptional dysregulation of the p73L/p63/p51/p40/KET gene in human squamous cell carcinomas: expression of Delta Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51 Br J Cancer 84 9 1235 1241 10.1054/bjoc.2000.1735 1:CAS:528:DC%2BD3MXkt1Olu74%3D 11336476 (Pubitemid 32511342)
71. G Pruneri L Pignataro M Manzotti N Carboni D Ronchetti A Neri BM Cesana G Viale 2002 p63 in laryngeal squamous cell carcinoma: evidence for a role of TA-p63 down-regulation in tumorigenesis and lack of prognostic implications of p63 immunoreactivity Lab Investig 82 10 1327 1334 1:CAS:528:DC%2BD38Xns1Cls74%3D 12379767
72. YK Chen SS Hsue LM Lin 2004 Expression of p63 (TA and deltaN isoforms) in human primary well differentiated buccal carcinomas Int J Oral Maxillofac Surg 33 5 493 497 10.1016/j.ijom.2003.10.023 15183414 (Pubitemid 38950217)
73. R Zangen E Ratovitski D Sidransky 2005 DeltaNp63alpha levels correlate with clinical tumor response to cisplatin Cell cycle 4 10 1313 1315 1:CAS:528:DC%2BD28XjvFOmsL4%3D 16123597
74. JW Rocco CO Leong N Kuperwasser MP DeYoung LW Ellisen 2006 p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis Cancer Cell 9 1 45 56 10.1016/j.ccr.2005.12.013 1:CAS:528:DC%2BD28XosFersQ%3D%3D 16413471 (Pubitemid 43069510)
75. DeYoung MP, Johannessen CM, Leong CO, Faquin W, Rocco JW, Ellisen LW (2006) Tumor-specific p73 up-regulation mediates p63 dpendence in squamous cell carcinoma. Cancer Res 66(19):9362-9368
76. CO Leong N Vidnovic MP DeYoung D Sgroi LW Ellisen 2007 The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers J Clin Investig 117 5 1370 1380 10.1172/JCI30866 1:CAS:528:DC%2BD2sXlt1Omtb4%3D 17446929 (Pubitemid 46718425)